June 15, GTJA Investment Group business partner Li Guolin and BGI's venture incubator blue rainbow CEO Liu Liang on accurate and precise medical health care is overheating prospects were discussed exchange.
Precision medicine has a certain bubble
Regarding the overheating of precision medicine, Liu Wei believes that the capital market always has a process of foaming and foaming out. To a certain extent, precision medicine has a certain bubble. "As far as I know, the original logistics company is going to buy some used second-hand test equipment, and then cooperate with the hospital to do genetic testing. From this point of view, precision medicine is really overheated." Liu Wei said.
In Liu Wei’s view, the so-called genetic test is equivalent to the ticket entrance, just like the Internet portal. The profit of genetic testing is limited, but providing value-added services can bring more profits. Such as personalized medication services and future applications and services. He compared genetic testing with the Internet and thought there was some similarity between the two. Internet payment and Internet video are models that are gradually derived from the development of Internet technology.
Due to monopoly and other reasons, the cost of gene sequencing has been at a high level and it is difficult to reduce. In 2012, Huada Gene acquired US CG company for 4 billion yuan. The sequencer was officially launched at the end of 2014. In the next decade, it is possible to reduce the cost of gene sequencing to $100. Liu Wei said that the decline in the cost of gene sequencing will not only change the part of gene sequencing, but also change the entire industry chain. The previous business model was profitable upstream. In March 2015, the Ministry of Science and Technology held the first national expert meeting on precision medicine strategy and proposed the China Precision Medical Plan. The meeting pointed out that by 2030, China will invest 60 billion yuan in precision medicine. Liu Wei said that China currently has half the number of sequencers in the world. When the cost of upstream sequencing declines, the original business model will be subverted. Therefore, Huada Fund created a blue rainbow in 2015 and developed related resources to downstream entrepreneurs. In addition to precision medicine, entrepreneurial innovation can be carried out in many fields.
A number of brokerage research reports estimate that the industry involved in the precision medical industry is trillions of yuan, and the directly related industry scale exceeds 10 billion yuan. In the field of life and health, the largest market currently is a pharmaceutical company. Patented drugs occupy a large market share, and 95% of companies are engaged in generic drugs. When analyzing the industry chain, the reason for the high cost of research and development is that the cost of finding a target is high. Liu Wei said that the company is currently calling small molecular libraries, and if the target is correct, it can be further developed. There is no need to build a research and development center and a library of DNA small molecule targets separately from R&D companies.
Liu Wei said that the application field based on genes is actually in its infancy. In simple terms, the size of the practitioners is not enough. At present, there are no more than 100,000 talents in China. Blue Rainbow is a platform that provides technology, data, intellectual property, capital and commerce. Blue Rainbow will channel the resources of this five sets of platforms to downstream partners, so that they can do innovation and entrepreneurship in these areas. Specifically, the field of gene application is very broad, and medicine, medicine (intestinal microbiota, etc.), food, agriculture, ecology (environmental management of livestock and poultry farming, etc.) and health have formed six major links in gene application.
"We have now seen a middle class of about 100 million (quantity), have healthy needs, and have the need for consumption upgrades, but local entrepreneurs are still accustomed to imitating the European and American markets, rather than the one billion middle class around China. Developing new health products.†Liu Wei said that whether it is medicine, medical care, food, or a variety of service products, if the company can really seize this market, it can truly realize supply-side reform, now the Chinese market. It will also give birth to its own leading enterprise. Liu Wei believes that the market is still in its infancy, and there is still much room for improvement.
Face Recognition Time Attendance
Face Recognition Time Attendance,Free Software Face Recognition Time Attendance,Face Recognition Attendance Machine,Face Fingerprint Time Attendance
Chongqing Huifan Technology Co., Ltd , https://www.hfsecuritytech.com